Clinical trials: Varenicline
Dry Eye Disease (DED)
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT04036292
- Testing
- OC-01 (varenicline) nasal spray
- Where
- 22 sites in United States
- Volunteers
- 758 people
- Sponsor
- Oyster Point Pharma, Inc.
Smoking Cessation
Smoking Cessation Study In Healthy Adolescent Smokers
The study is designed to see if varenicline combined with age appropriate (adolescent) smoking cessation counseling will help teens quit smoking.
- Trial name
- NCT01312909
- Testing
- Varenicline 1mg BID, Varenicline 0.5mg BID
- Where
- 80 sites in United States, Canada and 4 more
- Volunteers
- 312 people
- Sponsor
- Pfizer
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Smoking Cessation
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers.
- Trial name
- NCT00794365
- Testing
- Varenicline
- Volunteers
- 330 people
- Sponsor
- Pfizer
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking…
- Trial name
- NCT00139750
- Testing
- CP-526,555 (varenicline)
- Where
- 15 sites in Japan
- Volunteers
- 600 people
- Sponsor
- Pfizer